Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ImmuneWorks logo — Pioneering safe and effective treatments for autoimmune lung...

ImmuneWorks

Pioneering safe and effective treatments for autoimmune lung diseases through groundbreaking discoveries.

Founded 2006 Venture round Total: $735.00K Biotechnology, Health Care

General Information

Company Name ImmuneWorks
Founded Year 2006
Industries Biotechnology, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with ImmuneWorks. To contact ImmuneWorks, visit immuneworks.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About ImmuneWorks

ImmuneWorks, Pioneering safe and effective treatments for autoimmune lung diseases through groundbreaking discoveries. Founded in 2006 in Indianapolis, Indiana, ImmuneWorks focuses on developing immune tolerance therapies for patients suffering from severe autoimmune lung diseases. The company's innovative approach stems from its discovery that over half of idiopathic pulmonary fibrosis (IPF) patients are affected by antigen-specific autoimmunity, guiding their mission to create safe and effective treatments for these conditions. The latest investment of $60.00K was made in a Venture Round on 26 December 2013. ImmuneWorks operates in the Biotechnology and Health Care industries. As a content writer and startup/investor analyst, ImmuneWorks' innovative approach to developing immune tolerance therapies for severe autoimmune lung diseases is noteworthy. The company's specific focus on addressing antigen-specific autoimmunity in IPF patients sets it apart in the field of biotechnology and healthcare. The $60.00K investment in a Venture Round on 26 December 2013 underscores investor confidence in ImmuneWorks' mission and potential. With its pioneering work, ImmuneWorks presents an intriguing opportunity for investors seeking to support groundbreaking advancements in autoimmune disease treatment.

Taxonomy: ImmuneWorks, Autoimmune Lung Diseases, Immune Tolerance Therapies, Idiopathic Pulmonary Fibrosis, Antigen-Specific Autoimmunity, Treatment Development, Groundbreaking Discoveries, Scientific Research, Healthcare Innovation, Biomedical Science, Pulmonary Disease Therapies, Medical Research, Immunotherapy, Startup

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $60.00K -
26 Dec 2013
Debt Financing $375.00K -
17 Jul 2009
Seed Round $300.00K 1
BioCrossroads
BioCrossroads
30 Oct 2007

ImmuneWorks Alternatives & Competitors

View All Alternatives
ImmuneWorks vs
AnTolRx
AnTolRx

Innovative therapies for autoimmune diseases through targeted immune-regulation using proprietary na...

Series A
Biotechnology, Health Care
ImmuneWorks vs
Lung Therapeutics
Lung Therapeutics

Pioneering safer pathways in lung disease treatment with pharmaceutical solutions.

Series C
11-50 employees
Biotechnology, Health Care
ImmuneWorks vs
Kanyos Bio
Kanyos Bio United States

Kanyos Bio was founded with the goal of developing antigen-specific immune tolerance technology for...

Venture round
1 employees
Biotechnology, Health Care
View all alternatives

FAQ About ImmuneWorks

Pioneering safe and effective treatments for autoimmune lung diseases through groundbreaking discoveries.
ImmuneWorks was founded in 2006.
ImmuneWorks operates in Biotechnology and Health Care. Its work centres on ImmuneWorks, Autoimmune Lung Diseases, Immune Tolerance Therapies and Idiopathic Pulmonary Fibrosis.
ImmuneWorks has completed 3 funding rounds, raising a total of $735.00K. The latest funding stage is Venture round.
Top alternatives and competitors to ImmuneWorks include AnTolRx, Lung Therapeutics, Kanyos Bio, Apitope, DBV Technologies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ImmuneWorks and AnTolRx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ImmuneWorks, https://bouncewatch.com/company/immuneworks, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes